Us Biopreservation Market Report: Market Size & Forecast 2026

The U.S. biopreservation market encompasses products and services used to maintain the integrity and viability of biological specimens across a wide range of applications, including clinical research, drug discovery, regenerative medicine, and transplantation. The market's valuation of $4.25 billion in 2025 reflects a rapidly expanding ecosystem supported by cryogenic storage equipment, biobanking software, sample transport solutions, and specialized preservation media.

• •Key product segments include cryopreservation equipment, freezers and refrigerators, biobanking software platforms, and transport containers;
• •Demand is driven by clinical trials, stem cell research, genome sequencing initiatives, and the growing need for secure biological sample repositories.

The projected 17.52% CAGR is underpinned by a surge in cell and gene therapy development, with the FDA approving a growing number of allogeneic and autologous therapies requiring specialized preservation logistics. Personalized medicine initiatives and large-scale population biobanking programs, such as the All of Us Research Program, are further accelerating investment in storage infrastructure.

• •Expanding clinical trial activity involving biological samples, particularly in oncology and rare disease research;
• •Government and private investment in regenerative medicine and stem cell research programs;
• •Stringent FDA and NIH guidelines mandating proper sample handling, traceability, and biobanking standards.

Within North America, the United States dominates the market, accounting for the majority of regional revenue, with growing contributions from Canada's research and pharmaceutical sectors. The market is segmented by product type, equipment, media, and services, and by application, including therapeutic applications, research, and drug discovery.

• •Equipment (cryogenic freezers, liquid nitrogen systems) represents the largest product segment;
• •The research and drug discovery segment leads in application share, followed by regenerative medicine and transplantation;
• •The U.S. Northeast and West Coast regions account for a disproportionate share of biopreservation activity due to dense biotech clustering.

What are the recent trends and outlook?

Emerging trends shaping the market include the adoption of automated biobanking systems to reduce human error, growing interest in room-temperature sample preservation technologies to reduce reliance on liquid nitrogen, and the integration of artificial intelligence for sample inventory management. Looking ahead, the market is expected to sustain its strong growth trajectory through 2032 as the cell and gene therapy pipeline continues to mature and personalized medicine becomes more deeply embedded in clinical practice.

• •Automation and AI-driven sample management are reducing operational costs and improving data integrity in biobanking;
• •Next-generation preservation techniques, such as vitrification and lyophilization, are gaining traction for specific cell and tissue types;
• •Expanding FDA approvals for CAR-T and other advanced therapies will sustain demand for end-to-end biopreservation logistics and infrastructure.